glp-1 news november 2025 today Pipeline Update: - Prime Therapeutics GLP-1 Receptor Agonist Market Size

The study achieved an unprecedented 90% accuracy in distinguishing individuals with ME/CFS based entirely on these biological markers, definitively proving that gut dysbiosis is a core driver of the disease, not just a secondary symptom

Ibnosina J Med Biomed Sci

Farxiga/Forxiga (dapagliflozin) Disease area(s): Metabolic diseases Manufacturer(s): AstraZeneca 2024 Sales (USD): $7.72 billion Why it sold so well: In 2024, AstraZenecas Farxiga achieved robust sales growth, with revenues increasing by 21% year-over-year to $1.9 billion in the fourth quarter alone and by 28% compared to 2023, making it the companys top seller in 2024

1.16 Variants of hashimotos thyroiditis There are other variations of HT besides the traditional form

Evaluation of L-Carnitine Potential in Improvement of Male Fertility. Journal of Reproduction & Infertility , vol